Nasdaq
$1.81▼ 0.55%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $913,934.16Shares out 0.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
9- 4d agoPre-market26.10.21 20:018-KKey event#●●●#●●●
Genprex, Inc.
Genprex announced new peer-reviewed research identifying that TUSC2, the therapeutic gene in its REQORSA gene therapy, plays a critical role in brain aging and maintaining cellular processes. Researchers at Meharry Medical College found that TUSC2 deficiency in mice leads to mitochondrial dysfunction and protein homeostasis collapse, which correlates with human brain aging data.…more
$1.81-0.55%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.18Pre-market26.08.18 20:018-KKey event
Genprex, Inc.
On August 18, 2026, Genprex entered into a development and manufacturing agreement with a leading U.S.-based CDMO to scale up the manufacturing of its diabetes gene therapy program. This partnership enables the company to transition from research-grade production to cGMP-compliant clinical and commercial-ready output for future clinical trials.…more
$1.81-0.55%vs prev closeView filingShare - 9.18Overnight26.08.15 02:27filed10-QEarnings
Genprex, Inc.
Genprex, Inc. has filed its quarterly report on Form 10-Q for the period ended June 30, 2026, detailing its financial condition and operational results. The report includes updates on key research and license agreements, along with certifications from the CEO and CFO regarding financial reporting and internal controls.…more
$1.81-0.55%vs prev closeView filingShare
8 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoPre-market26.10.21 20:09#●●●#●●●
Genprex Highlights New Research on TUSC2 Gene's Role in Brain Aging
Genprex announced new peer-reviewed research in mice identifying the TUSC2 tumor suppressor gene as a key factor in maintaining cellular processes during healthy brain aging. While the study provides biological insights, it remains in the early research stage and lacks immediate clinical or commercial implications for the company.…more
$1.81-0.55%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 8.18Pre-market26.08.18 20:07
●●●●●●●● ●●●●● ●●●●●●
Genprex has entered into a development and manufacturing agreement with a U.S. CDMO to scale up production of its diabetes gene therapy for upcoming clinical trials. As the financial terms were not disclosed, this development is viewed as neutral.…more
$1.81-0.55%vs prev closeShareBenzinga
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report